Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608104 | 1.00 | GAA (0.47) | GAAABL1CA12CA1CA2 | |
| SCHEMBL23822989 | 0.84 | GAA (0.47) | GAAABL1CA12CA1CA2 | |
| SCHEMBL9140296 | 0.83 | GAA (0.49) | GAAABL1CA12CA1CA2 | |
| SCHEMBL11061303 | 0.81 | LMNA (0.53) | GAACA12CA1CA2CA7 | |
| SCHEMBL18393956 | 0.81 | CA12 (0.44) | GAAABL1CA12CA1CA2 | |
| SCHEMBL30466425 | 0.81 | CA12 (0.44) | GAAABL1CA12CA1CA2 | |
| SCHEMBL5961044 | 0.79 | GAA (0.49) | GAAABL1CA12CA1CA2 | |
| SCHEMBL23822990 | 0.79 | LMNA (0.41) | GAAABL1LMNAKDM4ETDP1 | |
| SCHEMBL23823369 | 0.79 | AKR1C2 (0.53) | KDM4ETDP1HTTTSHRMEN1 | |
| SCHEMBL23823337 | 0.78 | DHODH (0.41) | GAAKDM4EPOLBSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612390-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12516040-B2 | Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2025-07-01 | — | — | US | disclosed |
| EP-4556479-A1 | NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| EP-4442261-A2 | CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE | Constellation Pharmaceuticals, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4003532-B1 | CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4421072-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-114450279-B | Crystalline forms | 星座制药公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118236503-A | EZH2 inhibition combination therapy for the treatment of cancer | 星座制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113423710-B | Novel heterocyclic tricyclic derivative compounds and use thereof | 韩美药品株式会社 | 2024-06-14 | — | — | CN | disclosed |
| US-20180200238-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-19 | — | — | US | disclosed |
| US-20180200238-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-19 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017500-B2 | 1,3-benzodioxole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3329917-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-3121175-A1 | 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073335-A1 | 1,3-BENZODIOXOLE DERIVATIVE | EZH1, EZH2, BMI1 | GAA 3922/4885ABL1 169/4885CA12 3827/4885 |
| US-10017500-B2 | 1,3-benzodioxole derivative | EZH1, EZH2, BMI1 | GAA 3922/4885ABL1 169/4885CA12 3827/4885 |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | EZH2, EZH1, BMI1 | GAA 3512/4885ABL1 353/4885CA12 2957/4885 |
| US-20180200238-A1 | THERAPEUTIC AND/OR PROPHYLACTIC AGENT FOR ADULT T CELL LEUKEMIA/LYMPHOMA | MALT1, BCL9, BCL6 | GAA 1121/4885ABL1 127/4885CA12 889/4885 |
| US-12612390-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | NSD1, DOT1L, EHMT2 | GAA 2263/4885ABL1 3007/4885CA12 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.